文献速递头颈部肿瘤放疗

头颈癌患者放疗季节与结局:MACH-NC与MARCH荟萃分析

Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses.
PubMed 文献 · Radiother Oncol · 2023-11-11

基于MARCH(33项试验,11320例)和MACH-NC(29项试验,6276例)的头颈鳞癌个体患者数据,比较秋冬「暗季」与春夏「亮季」放疗对结局的影响。暗季放疗对无进展生存(PFS)和局部区域失败(LRF)均无获益,敏感性分析结果相似。

要点

  • 暗季放疗对PFS无获益:MARCH数据集HR 1.01(95%CI 0.97;1.05,p=0.72),MACH-NC数据集HR 1.00(95%CI 0.94;1.06,p=1.0)。
  • 暗季放疗对LRF无差异:MARCH数据集HR 1.00(95%CI 0.94;1.06,p=0.95),MACH-NC数据集HR 0.99(95%CI 0.91;1.07,p=0.77)。
  • 在至日前后治疗、接受完整放疗、同步放化疗及北方国家试验的预设敏感性分析中结果相似。

核心结论

  • 在MARCH和MACH-NC两个大型头颈鳞癌数据库中,放疗季节对PFS或LRF均无影响。

研究设计与样本

  • 分析MARCH(33项随机试验,11320例)和MACH-NC(29项随机试验,6276例)荟萃分析的个体患者数据。
  • 暗季定义为放疗中期日期在秋季或冬季,亮季为春季或夏季,以春分/秋分划分两期。
  • 主要终点为PFS,次要终点为LRF;采用按试验分层的Cox模型估计季节效应,并校正性别、肿瘤部位、分期和治疗。
  • 预设敏感性分析包括至日前后治疗的患者、接受完整放疗的患者、同步放化疗患者及北方国家试验。

主要发现

  • MARCH数据集暗季放疗对PFS无获益(HR 1.01,95%CI 0.97;1.05,p=0.72)。
  • MACH-NC数据集暗季放疗对PFS无获益(HR 1.00,95%CI 0.94;1.06,p=1.0)。
  • MARCH数据集LRF无差异(HR 1.00,95%CI 0.94;1.06,p=0.95)。
  • MACH-NC数据集LRF无差异(HR 0.99,95%CI 0.91;1.07,p=0.77)。
  • 敏感性分析显示相似结果。

关键数值与推荐

  • 暗季定义为放疗中期日期在秋季或冬季,亮季为春季或夏季,以春分/秋分划分。
  • 主要终点PFS,次要终点LRF;Cox模型按试验分层并校正性别、肿瘤部位、分期和治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A single institution retrospective study suggested that head and neck squamous cell cancer (HNSCC) patients receiving radiotherapy (RT) during "dark" season (fall/winter) may have better outcomes than those treated during "light" season (spring/summer), possibly secondary to seasonal variations in cell cycle progression. We investigated the impact of season of RT in two large, multi-institutional, prospective datasets of randomized trials. METHODS: Individual patient data from the MACH-NC and MARCH meta-analyses were analyzed. Dark season was defined as mid-radiotherapy date during fall or winter and light the reverse, using equinoxes to separate the two periods. Primary endpoint was progression-free survival (PFS) and secondary endpoint was locoregional failure (LRF). The effect of season was estimated with a Cox model stratified by trial and adjusted on sex, tumor site, stage, and treatment. Planned sensitivity analyses were performed on patients treated around solstices, who received "complete radiotherapy", patients treated with concomitant radio-chemotherapy and on trials performed in Northern countries. RESULTS: 11320 patients from 33 trials of MARCH and 6276 patients from 29 trials of MACH-NC were included. RT during dark season had no benefit on PFS in the MARCH (hazard ratio[HR]: 1.01 [95%CI 0.97;1.05],p=0.72) or MACH-NC dataset (HR:1.00 [95%CI 0.94;1.06],p=1.0. No difference in LRF was observed in the MARCH (HR:1.00 [95%CI 0.94;1.06,p=0.95) or MACH-NC dataset (HR:0.99 [95%CI 0.91; 1.07],p=0.77). Sensitivity analyses showed similar results. CONCLUSION: Season of RT had no impact on PFS or LRF in two large databases of HNSCC.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Limkin E, Blanchard P, Lacas B, et al. Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses. Radiother Oncol. 2023. PMID: 37956890. doi:10.1016/j.radonc.2023.110011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。